The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus
Clin Gastroenterol Hepatol. 2022 Feb;20(2):256-268.doi: 10.1016/j.cgh.2020.10.018. Epub 2020 Oct 16.
Jordan E Lake1, Turner Overton2, Susanna Naggie3, Mark Sulkowski4, Rohit Loomba5, David E Kleiner6, Jennifer C Price7, Kara W Chew8, Raymond T Chung9, Kathleen E Corey9
Author information
Division of Infectious Disease, University of Texas Health Sciences Center at Houston, Houston, Texas. Electronic address: Jordan.E.Lake@uth.tmc.edu.
Division of Infectious Disease, University of Alabama School of Medicine, Birmingham, Alabama.
Division of Infections Disease, Duke University School of Medicine, Durham, North Carolina.
Division of Infectious Disease, Johns Hopkins School of Medicine, Baltimore, Maryland.
Division of Gastroenterology, University of California San Diego School of Medicine, San Diego, California.
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Division of Gastroenterology, University of California San Francisco School of Medicine, San Francisco, California.
Division of Infectious Diseases, University of California Los Angeles School of Medicine, Los Angeles, California.
Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus, and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons with human immunodeficiency virus (PWH), chronic liver disease is the second leading cause of non-human immunodeficiency virus-related mortality. Between 20% and 63% of PWH have NASH, and 14% to 63% have NASH with fibrosis. However, little is known about the optimal diagnostic strategies, risk factors for, and treatment of NAFLD in PWH. Here, we review current data on and identify knowledge gaps in the epidemiology, pathophysiology, diagnosis, and management of NAFLD in PWH and highlight priorities for research.